Biology of Blood and Marrow Transplantation
Volume 15, Issue 2 , Pages 133-134 , February 2009

Defining Medicare Coverage for MDS Treatment and Research: A Time for Action?

  • C. Fred LeMaistre

      Affiliations

    • Corresponding Author InformationCorrespondence and reprint requests: C. Fred LeMaistre, MD, Texas Transplant Institute, 7711 Louis Pasteur #707, San Antonio, Texas 78229

References 

  1. Nimer S. Myelodysplastic syndromes. Blood. 2008;111:4841–4851
  2. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004. Blood. 2008;112:45–52
  3. Oliansky DM, Antin JA, Bennett JM, et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidenced-based review. Biol Blood Marrow Transplant.
  4. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia. 2006;20:1661–1672
  5. Lekakis L, de Lima M. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Expert Rev Anticancer Ther. 2008;8:785–798
  6. Finke J, Nagler A. Viewpoint: what is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning—is there still an upper age limit? A focus on myeloid neoplasia. Leukemia. 2007;21:1357–1362
  7. McClune B, Weisdorf DJ, DiPersio JD, et al. Non-myeloablative hematopoietic stem cell transplantation in older patients with AML and MDS: results from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood. 2008;12:135a;[abstract 346]

 Financial disclosure: See Acknowledgments on page 134.

PII: S1083-8791(08)01102-6

doi: 10.1016/j.bbmt.2008.12.492

Biology of Blood and Marrow Transplantation
Volume 15, Issue 2 , Pages 133-134 , February 2009

Article Tools